Delivery Order HHSN261201500036I-HHSN26100003
Award Date
9/24/15
Potential Completion Date
9/23/18
Potential Value
$574K
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Birmingham, AL 35294, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Department of Health and Human Services' National Cancer Institute to the University of Alabama at Birmingham (UAB) for the "Evaluation of STAT3 Antagonists in the Prevention of Mammary Cancer". The potential value of the contract is $492,314.00. The work is being performed under the National Cancer Institute's "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS" major...
The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a firm-fixed-price delivery order contract to the University of Alabama at Birmingham (UAB) for the evaluation of "clinical-ready" agents (bazedoxifene and lapatinib) in combination for the prevention of estrogen receptor-positive and estrogen receptor-negative mammary cancers. The contract, which is part of the Preclinical Prevent Cancer Program, has a potential value of...
This is a firm fixed-price delivery order contract issued by the Department of Health and Human Services' National Cancer Institute to the University of Alabama at Birmingham (UAB) for the "Prevention of Urinary Bladder Cancer with Two 'Clinically-Ready Agents (Everolimus and Naproxen) When Administered in Combination." The contract has a potential value of $432,272.00 and a completion date of April 30, 2020. It was awarded on July 9, 2018 and is part of the National Cancer Institute's...
This is a Firm Fixed Price delivery order awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Alabama at Birmingham (UAB) under the PREVENT Cancer Program (PREVENT) indefinite delivery contract. The contract has a ceiling value of $922,642.00 and no set-aside designation. The contract describes a research and development project in the area of biomedical basic research for the Preclinical Prevention Cancer Program. The work involves conducting preliminary...
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency, to the University of Alabama at Birmingham (UAB). The contract is for the "Evaluation of Agents/Protocols that Inhibit Two Major Pathways Involved in Human Urinary Bladder Cancer (PI3K, EGFR) and Protocols to Reduce Their Toxicity." It is part of the NCI's Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. The contract has a...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $636,313.00 firm fixed price delivery order contract to the University of Alabama at Birmingham (UAB) for "MULTI-ANTIGEN VACCINES FOR THE PRIMARY AND SECONDARY PREVENTION OF BLADDER CANCER." The period of performance is from September 15, 2017 to March 14, 2019. This contract is part of the National Cancer Institute's "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL...
This federal contract award was made by the National Cancer Institute, a civilian agency, to the University of Alabama at Birmingham (UAB) under the PREVENT Preclinical Drug Development Program (PREVENT). The $1,498,585.64 task order is for the research and development of a novel EPA analogue TP-252 and naproxen for colorectal cancer prevention in familial adenomatous polyposis (FAP) and Lynch syndrome models. The contract has no set-aside designation. UAB has performed numerous federal...
This is a firm fixed-price delivery order awarded by the Department of Health and Human Services, National Institutes of Health, National Cancer Institute to the University of Alabama at Birmingham (UAB) on September 17, 2018. The order, valued at $1,271,040.50, is for the preclinical development of the chemopreventive agent 4-methylumbelliferone (4-MU) under the agency's Preclinical Prevent Cancer Program. The work is being performed in Birmingham, Alabama and has a completion date of April 14,...
This federal contract was awarded by the National Cancer Institute, part of the Department of Health and Human Services, to the University of Alabama at Birmingham (UAB) to evaluate whether a concurrent retinoid X receptor agonist can enhance the efficacy of the HER2-IGFPB2-IGFLR vaccine in eliminating existing ductal carcinoma in situ and preventing progression of invasive breast cancer. The contract, valued at $930,464.00, is a delivery order under the PREVENT Cancer Program, a preclinical...
This federal contract was awarded by the U.S. Department of Health and Human Services (HHS) to the University of Alabama at Birmingham (UAB), a non-profit educational institution. The $383,382 Firm Fixed Price contract is for "Screening Various Chemopreventive Agents on MNU-Induced of Rat Mammary Tumors - WS #80" and has a completion date of September 29, 2005. The contract does not have a set-aside designation. UAB is a leading research university known for its expertise in areas such...